WO2002013817A1 - Traitements contre le cancer tolerant au cisplatine - Google Patents
Traitements contre le cancer tolerant au cisplatine Download PDFInfo
- Publication number
- WO2002013817A1 WO2002013817A1 PCT/JP2001/006798 JP0106798W WO0213817A1 WO 2002013817 A1 WO2002013817 A1 WO 2002013817A1 JP 0106798 W JP0106798 W JP 0106798W WO 0213817 A1 WO0213817 A1 WO 0213817A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- platinum complex
- cisplatin
- therapeutic agent
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a method for promoting the uptake of platinum complexes into cancer cells by dissolving or suspending a lipophilic platinum complex in odolated poppy oil fatty acid ethyl ester, and dissolving or suspending the lipophilic poppy oil fatty acid ethyl ester in cancer cells.
- the present invention relates to a therapeutic agent for cisplatin-resistant cancer, which comprises a lipophilic platinum complex as an active ingredient.
- Cisplatin is a platinum complex with a broad anticancer spectrum and strong antitumor effect, and as a central drug in multidrug therapy in the treatment of solid tumors, greatly contributes to the improvement of therapeutic results for various cancers are doing.
- side effects include severe nephrotoxicity, nausea and vomiting, and the presence of cancer resistant to cisplatin has become a major problem in cancer treatment.
- platinum complexes having 1,2-diaminocyclohexane (DACH) and 1,2-diaminocycloheptane as ligands cross-linked to cisplatin-resistant mouse leukemia cancer cell line L1210.
- Mechanisms of cancer cell resistance to platinum complexes such as cis-bratin include a decrease in platinum uptake in cells and daltathione metallothioney as an intracellular detoxification system. Increase in DNA concentration, DNA repair ability, and tolerance to DNA damage (JBiolchem. Pharmacol, 30, 2721-2723 (1981); Br. J. Cancer, 54, 239-243 ( 1986); Cancer Lett, 31, 163-169 (1986); Biochem. PharmcoL, 52, 1855-1865 (1996)).
- Ribosomal preparations containing cis-bis (neodecanato HIR, 2R) -1,2-diaminocycline hexaneplatinum (II) have been reported to be more effective against cisplatin-resistant cancers ⁇ Cancer Research, 48, 4509.4512 (1988); ibid., 53, 4913-4919 (1993)).
- Kishimoto et al. Drug Delivery System, 5, 243-247 (1990); Kishimoto et al "Reg. Cancer Treat, 1-2, 25-29 (1992)); Kishimoto et al" Biol Pharm. Bull, 23 , 344-348 (2000).
- An object of the present invention is to provide a method for promoting the uptake of a platinum complex into cancer cells, and a preparation capable of treating cisplatin-resistant cancer.
- the present inventors have found that the administration of a lipophilic platinum complex dissolved or suspended in LPD promotes the uptake of the platinum complex into cancer cells, and completed the present invention. That is, the gist of the present invention is as follows. [1] A method of promoting the uptake of platinum complexes into cancer cells by administering a lipid-soluble platinum complex dissolved or suspended in LPD.
- a therapeutic agent for cisplatin-resistant '1 live cancer comprising a lipid-soluble platinum complex dissolved or suspended in LPD as an active ingredient.
- the fat-soluble platinum complex has the formula:
- R is a substituted or unsubstituted, straight-chain or branched C 2 -C 24 saturated fatty acid residue or a straight-chain or branched-chain which may be substituted with a halogen atom. It represents a C 8 ⁇ C 24 unsaturated fatty acid residues.
- FIG. 1 is a schematic diagram of a membrane method for examining the cell growth inhibitory effect of SM-11355 / LPD and CDDPLPD.
- FIG. 2 is a diagram showing the cell growth inhibitory effect of SM-11355 / LPD on H4-II-E cells ( ⁇ ) and H4-II-E / CDDP cells ( ⁇ ) by the membrane method.
- “Cisbratin-resistant cancer” includes cancers that are naturally resistant and those that are acquired-resistant.
- Spontaneously resistant cancers are cancers that have an innate antitumor effect on cisplatin.
- Acquired resistant cancers are cancers that were initially susceptible to cisplatin but acquired acquired resistance as a result of continued cisplatin treatment. Even in one tumor, cisplatin-sensitive cancer cells and cisplatin-insensitive cancer cells are usually mixed. Thus, contact with cisplatin often kills highly sensitive cancer cells, resulting in acquisition-resistant cancer.
- the therapeutic agent for cisplatin-resistant cancer of the present invention is effective for both natural resistance and acquired-resistance cisplatin-resistant cancer, but is more preferably effective for acquired-resistant cisplatin-resistant cancer.
- Cisplatin-resistant cancers include second-generation platinum complexes (Carboplatin: Cancer Research, 47, 414-418 (1987)), iproplatin (Iproplatin: ibid., 47, 414-418 (1987)), Many also show cross-resistance to nedaplatin (Nedaplatin: cancer and chemotherapy, 23, 379-387 (1996)). Therefore, the present invention includes cancers that are resistant to other platinum complexes as long as they exhibit resistance to cis-bratin.
- lipid-soluble platinum complex examples include platinum complexes having a lipid-soluble base such as amine, diamine, and pyridine as a ligand.
- a lipid-soluble base such as amine, diamine, and pyridine as a ligand.
- SM-11355 JP-A-62-96, EP 193936
- Cis-bis neodecanato HIR, 2R) -1,2-diaminocycline hexaneplatinum
- eptaplatin Eptaplatin
- Oxaliplatin Oxaliplatin: Biolchem. Pharmacol, 52, 1855-1865 (1996)
- Lobaplatin Libaplatin: Pharmaceutical Research.
- Preferred fat-soluble platinum complexes include Examples include a platinum complex having (IR, 2R) -1,2-diaminocyclohexane.
- R is as defined above.
- the present invention also includes pharmaceutically acceptable salts of these fat-soluble platinum complexes and solvates such as hydrates thereof.
- the "C 2 ⁇ C 2 4 saturated fatty acid residue, linear or branched" for example acetic acid, flop port pan acid, butanoic acid, pentanoic acid, pivalic acid, hexanoic acid, octanoic acid, 2,2 Jimechinore octanoate, force purine acid, lauric acid, Mi Risuchin acid, Pa. palmitic acid, stearic acid, Arakidon acid, behenic acid, include residues such lignoceric acid, preferably, C 1 0 ⁇ C 2 4 saturated Fatty acid residues are preferred, and particularly preferred are residues such as myristic acid and 2,2-dimethyloctanoic acid.
- C 2 ⁇ C 2 4 saturated fatty acid residue linear or amount Edakusari substituted with halogen atom
- bromine atom or Youmoto C 2 -C 2 4 saturated fatty acid residue substituted straight or branched
- atom specifically, hexane Torifuruoro acetate, pentaerythritol full O b propane acid, to 5-click every mouth And residues such as acids.
- the “linear or branched C. to C 2 unsaturated fatty acid residue substituted with a halogen atom” includes one or more (for example, 2 to 7) chlorine atoms.
- Preparations in which a lipophilic platinum complex is dissolved or suspended in LPD are usually used as injections. For example, it can be administered into an artery leading to cancer tissue, and in the case of liver cancer, it can be administered to the hepatic artery.
- the concentration of the platinum complex in the solution or suspension may be, for example, about 10 to about 50 mg / ml.
- Formulations in which the lipophilic platinum complex is dissolved or suspended in LFD may be prepared by dissolving or suspending the lipophilic platinum complex in LFD immediately before administration. In that case, a freeze-dried preparation (JP-A-3-255025) or the like can be used as the fat-soluble platinum complex.
- the dose and frequency of administration of the lipophilic platinum complex vary depending on the patient's condition, age, body weight, dosage form, etc.
- It can be administered in the range of 300 mg, more preferably in the range of about 10 to about 200 mg. Further, the administration can be repeated at intervals of about 1 month to about 5 months, preferably about 2 months to about 3 months.
- SM-11355 freeze-dried preparation was manufactured by Sumitomo Pharma.
- CDDP was purchased from Wako Pure Chemical Industries and LPD was purchased from Mitsui Pharmaceutical.
- WST-1 (2- (4-iodophenyl)-3- (4-nitrophenyl)-5- (2,4-disulfopnenyl) -2Jbi-tetrazolium, sodmm salt) and 1-methoxy PMS (1.methoxy- 5-methylphenazinium methylsulfate) was purchased from Wako Pure Chemical.
- the MEM medium used was made by GIBCO. ⁇ Fetal bovine serum (FBS) is ICN The product made by BIOMEDICALS was used. Other reagents used were commercial grade products.
- Iwaki Glass 3810-006 6 well microplate is Iwaki Glass 3810-006.
- Iwaki Glass 3810-096 was used as a well microplate.
- Falcon 3090 was used as a cell culture insert.
- Iwaki Glass 3100-025 was used for Tissue culture flask.
- SM-11355 / LFD was prepared by adding LRD to the lyophilized SM-11355 product, adjusting it to 20 mg / ml, and then diluting it with LPD to the concentration to be studied.
- CDDP / LPD CDDP powder was finely ground in an agate mortar, LPD was gradually added and suspended, adjusted to 2 mg / ml, and diluted with LFD to the tested concentration.
- the WST-1 reagent was prepared by dissolving 4.1 mg of WST-1 in 3.1 ml of a 1-methoxy PMS solution (7 mg of 1-methoxy PMS was dissolved in 100 ml of PBS). 4 cells
- Rat liver cancer H4-II-E was obtained from Dainippon Pharmaceutical.
- H4-II-E cells were cultured in MEM medium, the CDDP concentration was increased stepwise from 0.1 pg / ml to 1.0 pg / ml for about one year.
- a CDDP-resistant cell line H4-II-E / CDDP
- a culture in vitro subcultured in a MEM medium containing CDDP (CDDP 1.0 pg / ml) was used.
- H4-nE / CDDP cells were It was approximately 10 times more resistant than 104- ⁇ - ⁇ cells.
- H4-II-E / CDDP cells were not multidrug-resistant cells because they did not show resistance to anticancer drugs such as doxorubicin and etoposide, which had a different mechanism of action from platinum complexes. This suggests that the decrease in intracellular platinum content contributes greatly to the mechanism of resistance of H4-II-E / CDDP cells to cisplatin.
- Cell growth inhibitory effect (membrane method) The cell growth inhibitory effect of SM-11355 / LPD was compared with that of CDDP / LPD. If the LPD preparation is added directly to the cell suspension, the cells will be damaged by direct contact between the LRD and the cells, so that the effect of the contained drug on the cell growth inhibition cannot be evaluated. Therefore, the LPD preparation and the cancer cells are brought into contact with each other via the membrane, and only the drug that has passed through the membrane is transferred into the cell suspension. We constructed and used this method.
- H4-II-E cells or H4-II-E / CDDP cells to 2.5 ⁇ 10 3 cells / ml, inoculate 2 ml / well into a 6-well microplate, and use the cell suspension as a control (for Day 0).
- WST-1 reagent by 20 ⁇ / well to the plate of the control, it was cultured for at 2, 3 in C0 2 Inkyubeta scratch. After the culture, the absorbance (measurement wavelength 450 nm, reference wavelength 650 nm) was measured using Immuno Header NJ-2001 (Inter Med).
- the medium was 2ml added, via a menu Nburen contacting the cell, C0 2 incubator one For 7 days.
- the cells were collected and seeded at 100 ⁇ 96 / well on a 96-well microplate.
- the WST-1 reagent was ⁇ Ka ⁇ by 20 l / well, after each in C0 2 incubator first predetermined incubation time, absorbance was measured. T / C (%) was determined from the following equation, and the IC 50 value was determined.
- T / C (%) (Absorbance of each treatment (Day 7)-Absorbance of control (Day 0)) / (Absorbance of LPD treatment alone (Day 7)-Absorbance of control (Day 0))
- X 100 2 and 3 are shown in FIGS. From Figure 3, CDDP / LPD of H4-II-E cells and: B4- IC 5 o values for II-E / CDDP cells is 0.57 g / ml and 9.6pg / ml, respectively, a difference of about 20 times Admitted.
- SM-11355 / LPD shows that the IC 50 values of SM-11355 / LPD for both cells were 3.1 pg / ml and 4.6 pg / ml, respectively, which were almost the same in both cell lines.
- SM-11355 / LPD also exhibited a cytostatic effect on H4-nE / CDDP cells. It was suggested that it was not affected by the acquisition mechanism.
- the amount of platinum incorporated into H4-II-E cells and H4-II-E / CDDP cells by SM-11355 / LPD and CDDP / LPD was measured using the membrane method described above.
- H4-II-E cells or H4-II-E / CDDP cells were adjusted to 4 ⁇ 10 5 cells / ml, seeded at 2 ml / well on a 6-well mac'oplate, and pre-cultured for 1 day.
- a cell culture insert is placed on each well of a 6-well microplate, and 2 ml of SM-11355 / LPD (50 pg / nil) and ⁇ CDDP / LPD (80 pg / ml) are added to each, and the membrane is inserted through the membrane.
- H4-II-E cells still contain more platinum than CDDP / LED. Moreover, in ⁇ 4- ⁇ -E / CDDP cells, a larger amount of platinum was taken into the cells.
- the present invention relates to a method for promoting the uptake of platinum complexes into cancer cells by dissolving or suspending a lipophilic platinum complex in odolated poppy oil fatty acid ethyl ester, and dissolving or suspending the lipophilic poppy oil fatty acid ethyl ester in cancer cells. It can be used as a therapeutic agent for cisplatin-resistant cancer containing a lipophilic platinum complex as an active ingredient.
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/344,239 US7253209B2 (en) | 2000-08-11 | 2001-08-08 | Remedies for cisplatin-tolerant cancer |
AU2001277711A AU2001277711A1 (en) | 2000-08-11 | 2001-08-08 | Remedies for cisplatin-tolerant cancer |
EP01955583A EP1319403A4 (en) | 2000-08-11 | 2001-08-08 | TREATMENTS AGAINST CANCER TOLERANT IN CISPLATIN |
JP2002501208A JP5096657B2 (ja) | 2000-08-11 | 2001-08-08 | シスプラチン耐性癌治療剤 |
US11/495,709 US7459482B2 (en) | 2000-08-11 | 2006-07-31 | Agent for treatment of cisplatin-resistant cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000244463 | 2000-08-11 | ||
JP2000-244463 | 2000-08-11 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10344239 A-371-Of-International | 2001-08-08 | ||
US11/495,709 Division US7459482B2 (en) | 2000-08-11 | 2006-07-31 | Agent for treatment of cisplatin-resistant cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002013817A1 true WO2002013817A1 (fr) | 2002-02-21 |
Family
ID=18735150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/006798 WO2002013817A1 (fr) | 2000-08-11 | 2001-08-08 | Traitements contre le cancer tolerant au cisplatine |
Country Status (6)
Country | Link |
---|---|
US (2) | US7253209B2 (ja) |
EP (1) | EP1319403A4 (ja) |
JP (1) | JP5096657B2 (ja) |
AU (1) | AU2001277711A1 (ja) |
TW (1) | TWI278314B (ja) |
WO (1) | WO2002013817A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006525368A (ja) * | 2003-05-02 | 2006-11-09 | アロネックス,ファーマシューティカルズ,インコーポレーテッド | 脂質白金錯体およびその使用方法 |
JP2008519036A (ja) * | 2004-11-08 | 2008-06-05 | バクスター・インターナショナル・インコーポレイテッド | チューブリン阻害化合物のナノ粒子組成物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
CN100457185C (zh) * | 2003-12-10 | 2009-02-04 | 株式会社东京大学Tlo | 二氨基环己烷合铂(ⅱ)与含聚羧酸链段的嵌段共聚物的配位络合物、其抗肿瘤剂 |
CZ300424B6 (cs) * | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8178564B2 (en) * | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168661B2 (en) * | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
US20110033528A1 (en) * | 2009-08-05 | 2011-02-10 | Poniard Pharmaceuticals, Inc. | Stabilized picoplatin oral dosage form |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
US20100260832A1 (en) * | 2007-06-27 | 2010-10-14 | Poniard Pharmaceuticals, Inc. | Combination therapy for ovarian cancer |
EP2178893A4 (en) * | 2007-07-16 | 2012-09-19 | Poniard Pharmaceuticals Inc | ORAL FORMULATIONS FOR PICOPLATIN |
CA2715353A1 (en) * | 2008-02-08 | 2009-08-13 | Poniard Pharmaceuticals, Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
CN104031091A (zh) * | 2014-04-11 | 2014-09-10 | 神威药业集团有限公司 | 一种脂溶性铂配合物的制备方法 |
WO2022217255A1 (en) * | 2021-04-07 | 2022-10-13 | Klotho Therapeutics, Inc. | Novel antitumor compounds and related methods of manufacture and use |
CN114642681B (zh) * | 2022-03-18 | 2023-08-29 | 中国科学院长春应用化学研究所 | 一种聚合物在顺铂解毒中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193936A1 (en) * | 1985-03-06 | 1986-09-10 | Sumitomo Pharmaceuticals Company, Limited | Liposoluble platinum (II) complex and preparation thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562275A (en) * | 1984-03-23 | 1985-12-31 | Bristol-Myers Co. | Antitumor platinum complexes |
US5384127A (en) * | 1985-10-18 | 1995-01-24 | Board Of Regents, The University Of Texas System | Stable liposomal formulations of lipophilic platinum compounds |
-
2001
- 2001-08-08 WO PCT/JP2001/006798 patent/WO2002013817A1/ja active Application Filing
- 2001-08-08 US US10/344,239 patent/US7253209B2/en not_active Expired - Fee Related
- 2001-08-08 AU AU2001277711A patent/AU2001277711A1/en not_active Abandoned
- 2001-08-08 EP EP01955583A patent/EP1319403A4/en not_active Withdrawn
- 2001-08-08 JP JP2002501208A patent/JP5096657B2/ja not_active Expired - Lifetime
- 2001-08-10 TW TW090119624A patent/TWI278314B/zh not_active IP Right Cessation
-
2006
- 2006-07-31 US US11/495,709 patent/US7459482B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0193936A1 (en) * | 1985-03-06 | 1986-09-10 | Sumitomo Pharmaceuticals Company, Limited | Liposoluble platinum (II) complex and preparation thereof |
Non-Patent Citations (7)
Title |
---|
DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA); accession no. STN Database accession no. 132:231576 * |
DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA); accession no. STN Database accession no. 132:329556 * |
DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS), (COLUMBUS, OHIO, USA); accession no. STN Database accession no. 134:216932 * |
KISHIMOTO S. ET AL.: "Cytotoxicity of cis-(((1R,2R)-1,2-cyclohexanediamine-N,N')bis (myristato))platinum (II) suspended in lipiodol in a newly established cisplatin-resistant rat hepatoma cell line", JPN. J. CANCER RES., vol. 91, no. 12, December 2000 (2000-12-01), pages 1326 - 1332, XP002948322 * |
KISHIMOTO S. ET AL.: "In vitro antitumor activity, intra-cellular accumulation and DNA adduct formation of cis-(((1R,2R)-1,2-cyclohexanediamine-N,N')bis (myristato)) platinum (II) suspended in lipiodol", JPN. J. CANCER RES., vol. 91, no. 1, January 2000 (2000-01-01), pages 99 - 104, XP002948323 * |
MIYAZAWA K. ET AL.: "In vitro antitumor activity, intra-cellular accumulation and DNA adduct formation of cis-(((1R,2R)-1,2-cyclohecanediamine-N,N')bis (myristato)) platinum (II) suspended in lipiodol", DRUG DELIVERY SYST., vol. 14, no. 5, 1999, pages 401 - 405, XP002948324 * |
See also references of EP1319403A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006525368A (ja) * | 2003-05-02 | 2006-11-09 | アロネックス,ファーマシューティカルズ,インコーポレーテッド | 脂質白金錯体およびその使用方法 |
JP2008519036A (ja) * | 2004-11-08 | 2008-06-05 | バクスター・インターナショナル・インコーポレイテッド | チューブリン阻害化合物のナノ粒子組成物 |
Also Published As
Publication number | Publication date |
---|---|
TWI278314B (en) | 2007-04-11 |
US7253209B2 (en) | 2007-08-07 |
EP1319403A1 (en) | 2003-06-18 |
US20060264502A1 (en) | 2006-11-23 |
EP1319403A4 (en) | 2009-07-08 |
JP5096657B2 (ja) | 2012-12-12 |
AU2001277711A1 (en) | 2002-02-25 |
US7459482B2 (en) | 2008-12-02 |
US20030171430A1 (en) | 2003-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7459482B2 (en) | Agent for treatment of cisplatin-resistant cancer | |
Pasetto et al. | The development of platinum compounds and their possible combination | |
US6673805B2 (en) | Platinum derivative pharmaceutical formulations | |
Baba et al. | Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs | |
Egerer et al. | Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients | |
US20150328234A1 (en) | Bufalin liposome, preparation method therefor and application thereof | |
CZ20021372A3 (cs) | Orální přípravky vhodné pro protinádorové sloučeniny | |
US20130034617A1 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
US5844001A (en) | Combination platinum chemotherapeutic/antiestrogen therapy for human cancers | |
US6288111B1 (en) | Combination cisplatin/tamoxifen therapy for human cancers | |
KR20100120674A (ko) | 콜레스타놀 유도체의 병용 용도 | |
JP2007528361A (ja) | 前立腺障害の治療および予防のための生薬組成物 | |
ES2747073T3 (es) | Combinación de RO5503781, capecitabina y oxaliplatino para el tratamiento del cáncer | |
US20040067952A1 (en) | Method and composition for treatment of cancer | |
AU2001277115A1 (en) | Use of estramustine phosphate in the treatment of bone metastasis | |
KR20020019967A (ko) | 에스트라무스틴 포스페이트 및 알부민의 비경구용 제형 | |
KR101964169B1 (ko) | 항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제 | |
US11554138B2 (en) | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy | |
Mohamed | Synthesis and biochemical study on the effect of a novel gallium complex on tumor cell Invasion and matrix metalloproteinase activity in vitro. | |
KR20110122682A (ko) | 콜레스탄올 유도체의 병용 용도 | |
US20040014729A1 (en) | Use of estramustine phosphate in the treatment of bone metastasis | |
QI | MECHANISTIC INSIGHTS INTO PLATINUM (IV) PRODRUG COMPLEXES OF CISPLATIN FOR CANCER THERAPY | |
WO2009104167A1 (en) | A substance or composition for the treatment of cancer | |
AU2002318983A1 (en) | Mathod and composition for treatment of cancer | |
WO2011066545A1 (en) | Treatment of human osteosarcoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 501208 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10344239 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001955583 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001955583 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |